Pompe disease drug safety checked in pregnant women and infants
NCT ID NCT05734521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gathers safety information from about 100 women with Pompe disease who received Nexviazyme while pregnant or breastfeeding, and from their babies. Researchers will track pregnancy complications, birth outcomes, and infant growth and development through the first year of life. The goal is to better understand any risks of the drug during pregnancy and breastfeeding. No new treatment is given; this is an observational safety registry.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POMPE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational site worldwide
RECRUITINGBridgewater, New Jersey, 08807, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a broader vitamin mix outperform standard prenatal supplements?
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Partnering up for birth: could Couples' classes boost satisfaction and memory?
- Which ripening method gets First-Time moms to vaginal delivery faster?
- Electronic monitors reveal HIV medication habits in pregnancy and beyond
- Could routine STI screening during pregnancy prevent preterm births?